Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors
{{output}}
Axitinib is an oral inhibitor of the VEGF, PDGF and colony stimulating factor-1 receptor tyrosine kinases and is currently in development by Pfizer Inc for the potential treatment of various solid tumors. Phase II trials with this agent alone or in combination... ...
